A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis by Philippe Devillier et al.
Devillier et al. BMC Medicine 2014, 12:71
http://www.biomedcentral.com/1741-7015/12/71RESEARCH ARTICLE Open AccessA meta-analysis of sublingual allergen
immunotherapy and pharmacotherapy in
pollen-induced seasonal allergic
rhinoconjunctivitis
Philippe Devillier1,2*, Jean-François Dreyfus2, Pascal Demoly3 and Moisés A Calderón4Abstract
Background: The capacity of sublingual allergen immunotherapy (SLIT) to provide effective symptom relief in
pollen-induced seasonal allergic rhinitis is often questioned, despite evidence of clinical efficacy from meta-analyses
and well-powered, double-blind, placebo-controlled randomized clinical trials. In the absence of direct,
head-to-head, comparative trials of SLIT and symptomatic medication, only indirect comparisons are possible.
Methods: We performed a meta-analysis of classes of products (second-generation H1-antihistamines, nasal
corticosteroids and grass pollen SLIT tablet formulations) and single products (the azelastine-fluticasone combination
MP29-02, and the leukotriene receptor antagonist montelukast) for the treatment of seasonal allergic rhinitis in adults,
adolescents and/or children. We searched the literature for large (n >100 in the smallest treatment arm) double-blind,
placebo-controlled randomized clinical trials. For each drug or drug class, we performed a meta-analysis of the effect
on symptom scores. For each selected trial, we calculated the relative clinical impact (according to a previously
published method) on the basis of the reported post-treatment or season-long nasal or total symptom scores:
100 × (scorePlacebo - scoreActive)/scorePlacebo.
Results: Twenty-eight publications on symptomatic medication trials and ten on SLIT trials met our selection
criteria (total number of patients: n = 21,223). The Hedges' g values from the meta-analyses confirmed the
presence of a treatment effect for all drug classes. In an indirect comparison, the weighted mean (range) relative
clinical impacts were -29.6% (-23% to -37%) for five-grass pollen SLIT tablets, -19.2% (-6% to -29%) for timothy
pollen SLIT tablets, -23.5% (-7% to -54%) for nasal corticosteroids, -17.1% (-15% to -20%) for MP29-02, -15.0%
(-3% to -26%) for H1-antihistamines and -6.5% (-3% to -10%) for montelukast.
Conclusions: In an indirect comparison, grass pollen SLIT tablets had a greater mean relative clinical impact
than second-generation antihistamines and montelukast and much the same mean relative clinical impact as
nasal corticosteroids. This result was obtained despite the presence of methodological factors that mask the
clinical efficacy of SLIT for the treatment of seasonal allergic rhinitis.
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Allergic rhinitis (AR) is one of the most common chronic
conditions worldwide [1-4]. Its high prevalence creates a
significant medical burden through sleep disorders, mood
disorders and impaired social functioning and perform-
ance at work [5-9]. This medical burden is associated with
a significant economic burden (estimated at $3.4 billion in
direct costs per year in the United States) [10].
The treatment goal in AR is to provide clinically rele-
vant symptom relief and improve the patient's quality of
life. Current international and national guidelines broadly
agree on the therapeutic approach [1-4,11-13]. As a front-
line treatment, H1-antihistamines are indicated in cases of
mild or intermittent respiratory allergy and can be com-
bined with nasal corticosteroids if the symptoms are not
sufficiently relieved. Allergen immunotherapy (AIT) is a
guideline-recommended therapeutic option for seasonal
allergic rhinitis (SAR) [1-4]. It can be administered as
subcutaneous allergen immunotherapy (SCIT) or sub-
lingual allergen immunotherapy (SLIT); SLIT is con-
sidered to have a better safety profile than SCIT, since
most adverse events are local and transient and do not
lead to interruption or cessation of treatment [14,15].
Large-scale, double-blind, placebo-controlled (DBPC)
randomized clinical trials, position papers and meta-
analyses have emphasized the efficacy and safety of
SLIT [16-22]. Drop and tablet formulations of grass
pollen SLIT products have been approved by regulatory
agencies in many countries for the treatment of seasonal
allergic rhinoconjunctivitis in adults and in children over
the age of five. However, variations in study design, pa-
tient selection, efficacy endpoints, allergen formulation,
product standardization and other parameters may have
given some physicians the impression that AIT products
(whether SCIT or SLIT) do not have a great impact on
symptoms. Direct, head-to-head comparison of AIT with
symptomatic medication is methodologically complicated,
not least because patients in AIT clinical trials are allowed
to take symptomatic ‘rescue’ medications when they wish.
Hence, only indirect comparisons are currently feasible.
Matricardi et al. compared SCIT with symptomatic medi-
cations by calculating the relative clinical impact (RCI)
[23]. The RCI is defined as the percentage difference be-
tween the total symptom score (TSS) or total nasal symp-
tom score (TNSS) obtained for active treatment versus that
obtained for placebo (see the Methods section and [23]).
When considering TSSs, Matricardi et al. concluded that
the weighted mean RCI of SCIT (-32.9 ± 12.7%) was sig-
nificantly greater than that of the antihistamine deslorata-
dine (-12.0 ± 5.1%). Similarly, when considering TNSSs,
the weighted mean RCI for SCIT (-34.7 ± 6.8%) was signifi-
cantly greater than that of the corticosteroid mometasone
(-31.7 ± 16.7%) and the leukotriene receptor antagonist
montelukast (-6.3 ± 3.0%) [23].Matricardi et al. reported on SCIT but not SLIT. Hence,
we decided to indirectly compare the RCIs of tablet for-
mulations of SLIT with the values for pharmacotherapy
(oral second-generation H1-antihistamines, nasal cor-
ticosteroids, the combined azelastine-fluticasone nasal
spray MP29-02 and the leukotriene receptor antagonist
montelukast) in exactly the same manner. We consid-
ered recent, well-powered, DBPC, randomized clinical
trials in SAR.
Methods
Study and data selection
We searched the literature for well-powered, double-blind,
randomized, controlled trials evaluating SLIT tablets,
H1-antihistamines, nasal corticosteroids, an azelastine-
fluticasone combination or leukotriene receptor antag-
onists having been granted marketing authorization
within the last 16 years (that is, 1997 to 2013) for the
indication of grass, tree or ragweed pollen-induced SAR
in adults and/or children. MEDLINE, Embase and the
Cochrane Library were searched using logical combina-
tions of the following terms: rhiniti*; allerg*; seasonal*;
rhinoconj*; hay fever; immunotherap*; immunolog*;
desensiti*; grass*; pollen*; pollinos*; SAR.
When performing meta-analyses, study selection is of
the utmost importance. We excluded trials with fewer
than 100 participants in the placebo arm or the active
treatment arm, trials lacking a true placebo group, chal-
lenge chamber studies and meta-analyses. The threshold
of 100 participants per arm was considered to be justi-
fied, since it (1) enabled the selection of all the SLIT tab-
let studies and the vast majority of the pharmacotherapy
studies and (2) prevented the selection of underpowered
studies. In fact, underpowered studies often suffer from
publication bias and contribute little information to meta-
analyses when two or more adequately powered large trials
are available [24-26]. We found at least three large stud-
ies for each single drug or drug class, whereas most of
the remaining studies were small. Hence, we included only
well-powered, large, multicenter, DBPC randomized clinical
trials of symptomatic treatments and grass pollen SLIT
tablets at the registered doses. In a recent report by Di Bona
et al. [22], a subgroup analysis according to the number of
centers showed that efficacy was higher in small single-
center studies than in multicenter studies. This difference
could be due to (1) publication bias and (2) exposure to
more homogeneous environmental conditions in single
center studies. In turn, this would lead to less variability in
the treatment response and a subsequently greater effect
size (relative to a multicenter study in which subjects from
different regions or even different countries are enrolled).
In order to increase consistency, reduce heterogeneity
and compensate for this bias, we selected multicenter
studies of symptomatic medications with at least 100
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large, multicenter studies).
Identified articles were cross-checked against those
listed in recent meta-analyses and reviews.
We extracted the following data from each selected
publication: (1) the active treatment and the dose, (2)
the number of participants in the full analysis set or
the intention-to-treat population in each treatment
arm, (3) the treatment duration (or, if several treatment
endpoints were quoted, the duration corresponding to
the subsequently calculated RCI), (4) the nature of the
symptom score used (a TNSS, a total ocular symptom
score (TOSS) and/or the rhinoconjunctivitis total symptom
score (RTSS)) and the number of symptoms scored. Indir-
ect symptom scores involving predominantly sleep-related
parameters (difficulty going to sleep, night-time awakenings
and so on) were not analyzed. Twelve- or 24-hour reflective
scores were selected in all cases.
In the SLIT tablet trials, the most frequently used criter-
ion for symptom severity (and, thus, for calculation of the
RCI in the present study) was the mean daily RTSS over
the whole pollen period. The RTSS comprises four nasal
symptoms and two ocular symptoms, each of which is
scored on a 4-point scale from 0 (the absence of symptoms)
to 3 (severe symptoms). In some trials, various symptom-
medication or adjusted scores were also evaluated, such as
(1) a mean symptom-medication score (RTSS/6 + (rescue
medication score)/2), ranging from 0 to 3), (2) the daily
average adjusted symptom score (AAdSS, in which a last-
observation-carried-forward method is used to adjust the
daily RTSS for rescue medication use [27]) and (3) the total
combined score, which is the sum of the daily RTSS and
the daily medication score [16,17].
Meta-analysis and calculation of the RCI
Symptom scores and (for SLIT only) combined symptom-
medication scores were assessed as outcome measures of
the treatment effect. Hedges' g was used to express mean
difference effect sizes. The I2 statistic was used to quantify
heterogeneity and reported P values are based on the
Q statistic (a statistic used for multiple significance
testing across a number of means). Meta-analyses were
performed for each drug class (or, for montelukast and
MP29-02, for each single drug). When the studies’ re-
sults differed only by the sampling error (that is, no het-
erogeneity), a fixed-effects model was applied to estimate
the overall Hedges' g using the MIX Pro add-on to Excel
(version 2.0.1.4., [28]). The I2 statistic can be interpreted
as the percentage of the total variability in a set of
effect sizes due to true heterogeneity (that is, between-
study variability). We considered that I2 values above
50% corresponded to substantial heterogeneity. When
substantial heterogeneity was observed, we performed
a sensitivity analysis by pooling data in a random effectsmodel and comparing the result with that of a fixed
effects model.
Given that effect sizes based on mean differences
(whether Hedges' g or the standardized mean difference)
do not measure the efficacy classically measured in clinical
trials, we used the mean post-treatment or seasonally aver-
aged symptom scores in the active treatment and placebo
groups to calculate the RCI. We analyzed each class of
symptomatic medication (or single medication for MP29-
02 and montelukast) and SLIT tablets in SAR by calculating
the RCI as 100 × (scorePlacebo - scoreActive)/scorePlacebo)
[23,29]. The RCIs were compared in a Kruskal-Wallis test
with correction for ties. Individual comparisons were per-
formed after correction with Simes' improved Bonferroni
procedure. For the SLIT tablet studies, we also calculated
the weighted mean RCI on the basis of the combined
symptom-medication scores.
Results
Study selection
For symptomatic medications, a total of 50 studies were
initially selected. Twenty-two of these studies were then
excluded because they failed to report (or did not enable
calculation of) post-treatment scores, which prevented cal-
culation of the RCI [see Additional file 1: Table S1] [23,29].
Hence, 28 publications on symptomatic medication trials
met our selection criteria [30-57] and were analyzed further
(Figures 1, 2, 3 and 4 and Additional file 2: Table S2). One
publication reported on both spring and fall pollen periods
[30] and several publications reported on different medica-
tions in separate treatment arms or several different trials
of the same medication [34,37-40,43,57], meaning that we
took account of a total of 39 separate active treatment arms
(23 for antihistamines, 9 for nasal corticosteroids, 4 for
montelukast and 3 for MP29-02 (a novel nasal spray
formulation of azelastine and fluticasone propionate)).
The selected symptomatic medication trials had been
performed in study populations comprising a mixture of
children, adolescents and adults, with the exception of four
studies in adults only (18 or more years old) [33,36,37,51]
and one study in children only (6 to 11 years old) [46]. All
but seven of the trials had been performed in the United
States. Symptoms were almost always rated on a 4-point
scale (0 = absent; 1 =mild; 2 =moderate; 3 = severe). The
most frequent symptom score was an eight-symptom TSS
(T8SS) for antihistamine trials and a four-symptom TNSS
(T4NSS: rhinorrhea, nasal congestion, sneezing and nasal
itching) for nasal corticosteroids and montelukast. Three
studies reported a TNSS and a TOSS separately [53-55].
Eleven publications on SLIT tablet trials met our selec-
tion criteria [16-19,58-64] (Figure 5 and Additional file 2:
Table S2). Three of the eleven SLIT tablet trials had been
performed in children and adolescents (5 to 17 years old)
[17,60,61], with the remainder in adults only (that is,
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Figure 1 RCI and meta-analysis of efficacy for H1-antihistamines (on the basis of symptom scores). N Act: number of subjects in the
active treatment group; Mean Act: mean score in the active treatment group; SD Act; standard deviation for the score in the active treatment
group; N Plac: number of subjects in the placebo group; Mean Plac: mean score in the placebo group; SD Plac: standard deviation for the score
in the placebo group; RCI: relative clinical impact; hg: Hedges' g; ci-: lower confidence interval; ci+: upper confidence interval; z: z score: p: p-value;
w: weighting; Des: desloratadine; Bila: bilastine; Lor: loratadine; Fex: fexofenadine; Cet: cetirizine. RCI, relative clinical impact.
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had been performed in the United States and Europe,
respectively. Although two of the SLIT trials tested dif-
ferent dosages of allergen [58,59], only the data for the
subsequently registered dosage (300 index of reactivity
(IR) and 75,000 standardized quality tablet (SQ-T)
units) were considered in the present study. The 11
SLIT tablet studies were further subdivided into those
testing five-grass pollen extracts [19,59,60,62,64] and
those testing Phleum pretense (timothy) pollen extracts
[16-18,58,61,63]. For the purposes of our analysis, we
studied data from single-season studies or from the
last year of treatment in multiple-season studies. The
study by Horak et al. [64] involved daily treatment
with a five-grass pollen SLIT tablet outside the pollen
season and symptom scoring during two- or four-hour
allergen challenges in an allergen challenge facility.
In view of these major differences with respect to
‘open-field’ trials, this study was not included in our
meta-analysis.Meta-analyses
One study [31] did not provide enough information on
the dispersion of the data and was not included in our
meta-analysis. The results of the meta-analysis for
H1-antihistamines as a class are shown in Figure 1.
We analyzed 23 treatment arms with a total of 10,206
patients. The overall Hedges' g (95% confidence interval
(CI)) was -0.39 (-0.43, -0.35) in a fixed effects model
and -0.39 (-0.45, -0.33) in a random effects model.
Figure 2 presents the results of the meta-analysis for
nasal corticosteroids, with nine treatment arms totaling
2,549 patients. The overall Hedges' g (95%CI) was –
0.55 (-0.63, -0.47) in a fixed effects model and -0.54
(-0.74, -0.34) in a random effects model. The results of
the meta-analysis for the leukotriene receptor antagonist
montelukast are shown in Figure 3. We analyzed four stud-
ies with a total of 2,946 patients. The Hedges' g (95%CI)
was –0.23 (-0.30, -0.16) in a fixed effects model and -0.25
(-0.36, -0.14) in a random effects model. The results of the
meta-analysis of three trials of an azelastine-fluticasone
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Figure 2 RCI and meta-analysis of efficacy for nasal corticosteroids (on the basis of symptom scores). N Act: number of subjects in the
active treatment group; Mean Act: mean score in the active treatment group; SD Act; standard deviation for the score in the active treatment
group; N Plac: number of subjects in the placebo group; Mean Plac: mean score in the placebo group; SD Plac: standard deviation for the score
in the placebo group; RCI: relative clinical impact; hg: Hedges' g; ci-: lower confidence interval; ci+: upper confidence interval; z: z score: p: p-value;
w: weighting; Beclo: beclomethasone. Mom: mometasone. RCI, relative clinical impact.
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three treatment arms featured a total of 1,703 patients. The
overall Hedges' g (95%CI) was –1.00 (-1.10, -0.90) in both
fixed effects and random effects models.
Lastly, the results of the meta-analysis for grass pollen
SLIT tablets as a class (totaling 3,819 patients in 10 studies)
are shown in Figure 5. Hedges' g (95%CI) was -0.30lP DScalP naeMcalP NtcA DStcA naeMtcA NydutS
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Figure 3 RCI and meta-analysis of efficacy for montelukast (on the ba
treatment group; Mean Act: mean score in the active treatment group; SD
Plac: number of subjects in the placebo group; Mean Plac: mean score in t
placebo group; RCI: relative clinical impact; hg: Hedges' g; ci-: lower confide
weighting. RCI, relative clinical impact.(-0.36, -0.23) in a fixed effects model and -0.31 (-0.39, -0.22)
in a random effects model. We also performed separate
analyses for the two different SLIT tablet products. The
four studies of five-grass pollen tablets featured a total of
1,612 patients; Hedges' g (95%CI) was -0.40 (-0.50, -0.30)
in a fixed effects model and -0.40 (-0.52, -0.29) in a random
effects model. The five studies of timothy pollen tabletswpz+ic-icghICRca
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Figure 4 RCI and meta-analysis of efficacy for an azelastine-fluticasone combination (on the basis of symptom scores). N Act: number of
subjects in the active treatment group; Mean Act: mean score in the active treatment group; SD Act; standard deviation for the score in the
active treatment group; N Plac: number of subjects in the placebo group; Mean Plac: mean score in the placebo group; SD Plac: standard
deviation for the score in the placebo group; RCI: relative clinical impact; hg: Hedges' g; ci-: lower confidence interval; ci+: upper confidence
interval; z: z score: p: p-value; w: weighting. RCI, relative clinical impact.
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TOTAL N 3819 -0.30 -0.36 -0.23 -9.16 0.000 Fixed
Five-grass Timothy -0.31 -0.39 -0.22 -7.10 0.000 Random
Q 5.69 4.73
p 0.22 0.45
I2 29.75 0.00
weighted mean RCI -29.6 -19.2
Figure 5 RCI and meta-analysis of efficacy (symptom scores) for five-grass pollen SLIT tablets and timothy pollen SLIT tablets. N Act:
number of subjects in the active treatment group; Mean Act: mean score in the active treatment group; SD Act; standard deviation for the score
in the active treatment group; N Plac: number of subjects in the placebo group; Mean Plac: mean score in the placebo group; SD Plac: standard
deviation for the score in the placebo group; RCI: relative clinical impact; hg: Hedges' g; ci-: lower confidence interval; ci+: upper confidence
interval; z: z score: p: p-value; w: weighting. RCI, relative clinical impact.
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was -0.23 (-0.31, -0.16) with both fixed effects and ran-
dom effects models. A meta-analysis of the combined
symptom–medication scores (Additional file 3: Table S3)
in grass pollen SLIT trials (excluding the trials by Bufe
et al. and by Murphy et al., for which combined scores
were not available [61,63]) led to similar findings
(Hedges' g (95%CI): -0.36 (-0.44, -0.28) with both fixed
and random effects models). Hence, our meta-analyses
confirmed the presence of an effect on symptoms for
all drug classes (or for a single drug, for MP29-02 and
montelukast), including grass pollen SLIT tablets.
Relative clinical impact
In order to compare our results for SLIT with those
for symptomatic medications, we calculated the RCI
(on symptom scores) for each study (Figures 1, 2, 3 and 4).
In almost all cases, we and Matricardi et al. [23] calculated
the same RCI for a given trial. The calculated weighted
mean (range) RCIs were -29.6% (-23% to -37%) for five-
grass SLIT tablets, -19.2% (-6% to -29%) for timothy SLIT
tablets, -15.0% (-3% to -26%) for second-generation
H1-antihistamines, -23.5% (-7% to -54%) for nasal cor-
ticosteroids, -17.1% (-15% to -20%) for the azelastine-
fluticasone combination MP29-02 and -6.5% (-3% to -10%)
for montelukast. It should be noted than in head-to-head
studies, MP29-02 showed greater efficacy than intranasal
fluticasone [57]. Importantly, comparison of these RCIs
indicated that the grass SLIT tablets' effect on symp-
toms (P < 0.05) was significantly greater than that of H1
antihistamines and the leukotriene receptor antagonist
montelukast and was similar to that of nasal corticoste-
roids and MP29-02. In the allergen challenge trial by
Horak [64], the RCI was -29% (based on mean scores)
or -33% (based on median scores). These values are slightly
higher than the weighted mean RCIs (based on symptom
scores or combined scores) calculated for natural exposure
trials of the five-grass pollen SLIT tablets.
The largest RCI (-54%) was obtained for mometasone
in a study by Graft et al. [50]. This high value may have
been due to the atypical study design, since mometasone
furoate nasal spray was administered prophylactically for
four weeks prior to the expected onset of the ragweed
pollen season and then for a further four weeks; efficacy
was calculated over the third and fourth weeks of the
season.
We also calculated the RCIs for the two types of grass
SLIT tablets on the basis of combined symptom and
medication scores. There were no marked differences
with respect to the RCIs calculated from the symptom
score alone (Figure 5 and Additional file 3: Table S3).
The weighted mean RCI was -28.8% (instead of -29.6%
on the basis of the symptom scores) for the five-grass
pollen SLIT tablets and -25.8% (instead of -21.5%) forthe timothy pollen SLIT tablets. The overall RCI for
grass pollen SLIT tablets as a class (that is, five-grass
and timothy) was -28.8% (instead of -23.6%).
Discussion
Meta-analyses
Our meta-analyses confirmed the presence of an effect
on symptoms for all drug classes (or single drugs, for
MP29-02 and montelukast), including grass pollen SLIT
tablets. The Hedges' g values calculated here were com-
patible with those found in the literature data. For ex-
ample, we found a value of 0.39 for the antihistamines as
a class; this may be compared with Compalati et al.'s
value of 0.42 for fexofenadine [65], Mösges et al.'s values
of 0.59 for levocetirizine and 0.21 for loratadine [66],
and Compalati and Canonica's value of 0.37 for rupata-
dine [67]. In contrast, Matricardi et al. calculated a value
of 1.00 for antihistamines as a class; however, the latter
meta-analysis included a number of small studies with
large effect sizes [23]. The values for montelukast are
very consistent: 0.23 in the present study and 0.24 ac-
cording to both Matricardi et al. [23] and Rodrigo et al.
[68]. Lastly, we calculated a Hedges' g of 0.55 for corti-
costeroids as a class; Matricardi et al.'s value for mome-
tasone was 0.47 [23]. These similarities indicate that our
selected studies form a valid basis for further analysis
(that is, calculation of the RCI).
The RCI of SLIT is as large as that of nasal corticosteroids
We studied the degree of symptom relief (relative to placebo)
provided by recently approved symptomatic medications
and tablet formulations of SLIT products. Despite mechan-
istic differences in the mechanism of action of these
two treatment approaches, the current evidence from
the recent, well-powered, stringent, clinical studies an-
alyzed here suggests that grass pollen SLIT tablets pro-
vide a greater degree of symptom relief in SAR than
certain symptomatic drugs or drug classes (such as the
leukotriene receptor antagonist montelukast and second-
generation H1-antihistamines) and much the same degree
of relief as nasal corticosteroids and an azelastine-
fluticasone combination. This finding is especially striking
because a number of methodological factors reduce the
apparent magnitude of effect in AIT clinical trials. It is
problematic to compare the symptomatic medication
RCIs calculated in the present study with mean values
in the meta-analyses performed and reported by Wilson
et al. (-18% for nasal corticosteroids, -7% for oral anti-
histamines and -5% for montelukast [69]) and Benninger
et al. (-40.7% for nasal corticosteroids and -23.5% for
oral antihistamines [70]) because the latter studies used a
different calculation method. However, the order of
these drug classes in each analysis is consistent (nasal
corticosteroids > oral antihistamines > montelukast). It
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atic drug class, members may differ in their efficacy
and tolerance. Using a therapeutic index score, Schäfer
et al. suggested that there were differences between
intranasal corticosteroids [71]. Likewise, a meta-analysis
from open-label prospective observational studies per-
formed by Mösges et al. suggested that levocetirizine is
significantly more effective than desloratadine, ebastine
and fexofenadine [72]. However, a number of the studies
analyzed in the present paper or in the literature made
head-to-head comparisons between marketed nasal cor-
ticosteroids or between antihistamines. The differences
in efficacy were either not significant or were inconsist-
ent from one study to another [33,34,44,50,51].
Calculation of the RCI
The World Allergy Organization's definition of the RCI
(as applied by Matricardi et al. [23]) is based solely on
the relative mean active treatment versus placebo differ-
ence in scores calculated over a defined period (usually
the pollen season as a whole for the SLIT studies) [29].
The method is easily applicable to SLIT or SCIT trials
lacking a low, pre-season baseline score but its use in
short-term pharmacotherapy trials (in which a high, peak-
season baseline score is available) can be criticized. Indeed,
we excluded a number of pharmacotherapy trials in which
the RCI was estimated as the percentage difference between
reductions in scores (that is, without reporting the baseline
and final scores). In the absence of head-to-head SLIT tab-
let versus pharmacotherapy trials (which would be difficult
to design, implement and interpret), we believe that the
RCI affords a meaningful comparison.
Methodological differences in the clinical assessment of
SLIT products versus symptomatic medications
It was only in 2009 that the European Medicines Agency's
guideline on the clinical development of AIT products [73]
came into force after being released as a draft for con-
sultation in 2007. The recent clinical development of
tablet SLIT formulations has closely followed these
evidence-based guidelines. However, several methodo-
logical factors decrease the apparent RCI for SLIT and,
conversely, increase the apparent RCI for symptomatic
medications (below and Additional file 4: Table S4).
Total versus partial symptom scores
The etiological nature of AIT means that clinical trials
in this field generally use total symptom scores, in which
nasal symptoms, ocular symptoms and (sometimes) other
local or individual parameters (coughing, wheezing, ear
itch, and so on) are taken into account. In symptomatic
medication trials and depending on the drug's pharmaco-
logical action, certain symptoms are sometimes excluded
from the efficacy scores. The failure to score individualsymptoms that are at least partly treatment-refractive
(for example, nasal symptoms for antihistamines) may
thus prompt overestimation of the RCI for some symp-
tomatic medications.
Rescue medication use
For ethical reasons, rescue medications cannot be pro-
hibited in month- or year-long SLIT or SCIT trials. The
experimental data (that is, medication scores) show that
rescue medication use is greater in placebo groups than
in active treatment groups. This factor reduces the dif-
ference in mean symptom scores between the SLIT and
placebo groups and thus leads to underestimation of the
RCI for SLIT products. Overall, there were few marked
differences between the RCIs calculated from symptom
scores and those calculated from combined scores in a
given trial (respectively, -27.4% and -30.8% for Didier et al.
[59], -27.9% and -26.0% for Wahn et al. [60], and -18.3%
and -20.05% for Nelson et al. [16], for example).
Trial design and duration, patient recruitment,
randomization and baseline scores
AIT products and pharmacotherapy products differ mark-
edly in terms of the typical study period in SAR. Symptom-
atic medication trials typically evaluate symptom relief over
a two-week period during the pollen season. In contrast, the
efficacy of SLIT (and indeed SCIT) is studied over a whole
pollen season (up to two months).
Disease severity
The mean disease severity in SLIT (and SCIT) trials is
usually lower than in symptomatic medication trials, for
two main reasons: trial duration and patient recruitment.
Firstly, allergen exposure (and thus disease severity) in
SLIT trials will fluctuate over the month- or year-long
study period, giving peaks and troughs of disease activ-
ity. In contrast, symptomatic medications are tested
over short periods at or around the pollen peak, when
disease severity is high and highly symptomatic pa-
tients can be easily recruited. In a SLIT trial, treatment
is initiated before the start of the expected pollen sea-
son (that is, when patients are asymptomatic). Hence,
investigators can never be sure that randomized patients
will actually be symptomatic during the coming study.
This limitation ‘dilutes’ the level of disease severity. This
SLIT versus symptomatic drug difference can be exempli-
fied by estimating the relative SAR severity in the placebo
group. In the trials selected in the present meta-analysis,
we expressed the mean symptom score as a percentage of
the maximum possible symptom score. In the SLIT trials,
the mean (range) relative SAR severity score in the pla-
cebo group was 24.7% (18% to 34%). In the symptomatic
medication trials, the mean (range) relative SAR severity
score was 48.7% (30% to 67%) in antihistamine trials,
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(58% to 64%) in montelukast trials and 66.5% (64% to 68%)
in trials of the azelastine-fluticasone combination.
In SLIT trials, there are several lines of evidence to
suggest that greater mean disease severity in patients is
associated with a greater RCI (and, conversely, that low
mean disease activity in patients reduces the apparent RCI).
It is possible to identify high-severity patients within a
SLIT trial, so that this subpopulation can then be more
fairly compared with high-severity patients in symptom-
atic medication trials. Firstly, Bufe et al.'s study [61] in a
pediatric population found RCIs of -24% for the grass
pollen season as a whole, -25% for the 15-day peak grass
pollen season and -28% for the ‘high-level’ grass pollen
season (the period over 30 grains/m3). Hence, for SLIT
products, low disease activity at the start and end of
the pollen season reduces the mean RCI calculated
over the season as a whole. Secondly, a novel way to
focus on patients in SLIT trials with high disease burdens
(thus mirroring experimental conditions in symptomatic
medication trials) involves a prespecified, post hoc tertile
analysis. Howarth et al. has applied this approach [74]
to three large SLIT clinical trials [19,59,60]. Study cen-
ters were grouped into low, middle and high tertiles
according to the average RTSS or AAdSS observed in
each center's placebo patients. The high-severity tertile
(in which the relative severity of SAR was 34%, rather
than 27% for the placebo group as a whole) corresponds
most closely to the population typically recruited in
symptomatic medication trials. After calculating the RCIs
on the basis of the average RTSS and the AAdSS for all
three studies, Howarth et al. found that the greatest RCI
was always observed in the high tertile, that is, the centers
in which patients were most strongly affected by pollen
[74]. When calculated from the AAdSS for the high
tertile in four studies of five-grass pollen SLIT tablets,
we found that the weighted mean (range) RCI was –37.1%
(-26% to -45%). Thirdly, Durham [75] published an
analysis of ‘days with severe symptoms’ in clinical trial
patients taking a timothy grass tablet. Even though
this analysis was based on individual severity scores
(rather than groups of centers), Durham et al. came to
the same conclusion: the more severe the symptoms,
the greater the clinical impact of SLIT. Recently, Durham
et al. [76] have further shown that the size of the treat-
ment effect over five pollen seasons in a long-term trial
of timothy SLIT tablets was highly correlated with the
cumulative pollen exposure at the start of the season.
In particular, the SLIT versus placebo difference in the
weighted rhinoconjunctivitis combined symptom and
medication score increased as the pollen count increased
(reaching about 33% for the highest pollen count).
An interesting question relates to whether the RCI for
SLIT products and symptomatic medications changesover time during long-term use (that is, from one year
or treatment season to another). The multiseason stud-
ies of grass pollen SLIT tablets provide a few indications
[18,19]. In the trial by Durham et al., the RCIs for the
treatment years one, two and three (based on the RTSS)
were -0.31, -0.36, and -0.29, respectively [18]. On this
basis, Durham et al. considered that the ‘reductions in
rhinoconjunctivitis symptom and medication scores and
the increase in quality of life and percentage symptom-
and medication-free days one year after treatment were
all similar to the treatment effect at the end of the three-
year treatment period’ [18]. Based on the three-season data
for the AAdSS in the study by Didier et al., the respective
RCI for seasons one, two and three were -0.20, -0.34,
and -0.37 [19]. However, it must be borne in mind that
the mean pollen count (and, thus, the severity of disease)
varied from one treatment year or season to the next. This
factor is likely to be the major factor involved in the vari-
ation of the measured RCI (see below). Due to the absence
of a persistent, long-term effect of symptomatic drugs,
there is no reason to believe that their efficacy in SAR will
change year-on-year.
In summary, an ‘unbiased’ comparison between SLIT
and symptomatic medications would have to be performed
with the most similar possible levels of pollen exposure and
symptom severity. As things stand, one can hypothesize
that trials of SLIT (generally performed in patients with
mild-to-moderate symptoms) tend to underestimate the
RCI for these formulations. Estimation of SLIT's effect
size on the basis of the RCI observed for the high disease
tertile is far from perfect. However, in the absence of ro-
bust, large-scale, head-to-head clinical trials, this tertile
is an approximation of the conditions encountered in a
symptomatic drug trial.
Limitations of the RCI approach
Although we restricted our selection to investigations of
pollen-induced SAR, the studies of symptomatic medi-
cations (notably the H1-antihistamines) were variously
performed in spring, summer and fall in patients with
SAR induced by tree, grass and/or weed pollens. This
is an additional source of heterogeneity. In contrast,
the SLIT studies all concerned grass-pollen-induced
SAR occurring in late spring/early summer. As men-
tioned above, SLIT trials and symptomatic medication
trials differ in terms of the characteristics of the study
population and the scoring systems used. The scores in
SLIT trials tend to be averaged over a treatment season,
whereas those in symptomatic medications trials tend to
be point measurements at the end of a short treatment
period. Furthermore, the RCI takes account of differences
in scale because the comparison is always made with the
placebo group in the same trial. In the term ‘relative clin-
ical impact’, the word ‘relative’ means ‘the clinical impact
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the RCI can provide a valid (albeit indirect) comparison
between SLIT and symptomatic medications.
Conclusions
In an indirect comparison (as previously performed for
SCIT by Matricardi et al. [23]), the administration of grass
pollen SLIT tablets was associated with a greater RCI
(versus placebo) on symptoms than that provided by
second-generation H1-antihistamines and a leukotriene
receptor antagonist - medications that clearly ‘work’ in
clinical practice and whose efficacy is not called into ques-
tion. These RCIs were obtained despite the presence of
methodological factors that mask the efficacy of SLIT.
Additional files
Additional file 1: Table S1. List of studies initially considered but not
selected, together with the reasons for non-selection.
Additional file 2: Table S2. Pharmacotherapy and grass pollen SLIT
tablet trials in seasonal allergic rhinitis. TnNSS: total nasal symptom score
with n symptoms; TnSS: total symptom score with n symptoms; TnOSS:
total ocular symptom score with n symptoms; QD: once daily, BID; twice
daily; IR: index of reactivity; SQ-T: standardized quality tablet. RTSS:
rhinoconjunctivitis total symptom score; ‡as used in the meta-analysis;
*as used in the meta-analysis and generally (but not always) the study's
stated primary efficacy criterion.
Additional file 3: Table S3. RCI and meta-analysis of efficacy
(based on combined scores) for grass pollen SLIT tablets. N Act: number of
subjects in the active treatment group; Mean Act: mean score in the active
treatment group; SD Act; standard deviation for the score in the active
treatment group; N Plac: number of subjects in the placebo group; Mean
Plac: mean score in the placebo group; SD Plac: standard deviation for the
score in the placebo group; RCI: relative clinical impact; hg: Hedges' g; ci-:
lower confidence interval; ci+: upper confidence interval; z: z score: p:
P-value; w: weighting; ACS: average combined score; TCS: total combined
score = daily symptom score + daily medication score; WCS: weighted
combined score = (daily symptom score/maximum symptom score))/
(1- daily medication score - maximum symptom score).
Additional file 4: Table S4. Methodological differences in the
evaluation of treatments for pollen-induced seasonal allergic rhinitis.
T6SS: total symptom score with six individual symptoms; T4SS: total
symptom score with four individual symptoms.
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AAdSS: Average Adjusted Symptom Score; ACS: average combined score;
Act: active treatment; AIT: allergen immunotherapy; AR: allergic rhinitis;
Beclo: beclomethasone; BID: twice daily; CI: confidence interval, DBPC,
double-blind, placebo-controlled; hg: Hedges' g; IR: index of reactivity;
Mom: mometasone; Plac: placebo; QD: once daily; RCI: relative clinical
impact; RTSS: Rhinoconjunctivitis Total Symptom Score; SAR: seasonal allergic
rhinitis; SCIT: subcutaneous allergen immunotherapy; SLIT: sublingual allergen
immunotherapy; SQ-T: standardized quality tablet; TCS: total combined score;
TnNSS: total nasal symptom score with n individual symptoms; TNSS: total
nasal symptom score; TnSS: total symptom score with n individual
symptoms; TOSS: total ocular symptom score; TSS: total symptom score;
w: weighting; WCS: weighted combined score.
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